Track topics on Twitter Track topics that are important to you
Chimeric antigen receptor T-cell receptor (CAR-T) and CAR-modified natural killer (CAR-NK) therapeutics can be produced faster and at less cost, Cesca Therapeutics says, through the cellular processing technology covered by a recently-awarded patent. Cesca said Friday that U.S. Patent No. 9,695,394, titled “Cell Separation Devices, Systems, and Methods,” has been awarded to SynGen—whose cell processing assets were acquired earlier this month by Cesca’s 80%-owned device subsidiary ThermoGenesis. The patented technology relates to automated isolation of rare stem, progenitor or immune cell populations from blood, bone marrow, leukapheresis product, and other sources, while maintaining the viability of the cells under asceptic conditions. The patented technology has been incorporated into Cesca’s proprietary CAR-TXpress™ platform, designed to integrate multi-component automation steps that include T-cell isolation, purification, culture expansion and washing, and single cassette-based automated -196°C cryopreservation and retrieval. Cesca says its automated cell processing system provides greater cell yields ...
Original Article: With New Patent, Cesca Eyes Faster, Less Costly CAR-T Cell ProductionNEXT ARTICLE